Levofolinic acid

Drug Profile

Levofolinic acid

Alternative Names: Calcium levofolinate; Calcium levoleucovorin; FUSILEV; Isovorin; Levofolinate; Levofolinate calcium; Levoleucovorin; Levoleucovorin calcium pentahydrate

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Spectrum Pharmaceuticals
  • Class Antidotes; Antineoplastics; Formyltetrahydrofolates; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia; Colorectal cancer; Osteosarcoma

Most Recent Events

  • 27 Oct 2016 Chemical structure information added
  • 27 Oct 2015 First generic equivalent available in USA for Osteosarcoma
  • 13 Jul 2013 Spectrum Pharmaceuticals withdraws a phase I trial prior to enrolment for Stomatitis (prevention and reduction) in patients with non-Hodgkin's lymphoma in USA (NCT01789723)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top